PL3139914T3 - Związki stosowane w leczeniu chorób i schorzeń okulistycznych - Google Patents
Związki stosowane w leczeniu chorób i schorzeń okulistycznychInfo
- Publication number
- PL3139914T3 PL3139914T3 PL15720340.7T PL15720340T PL3139914T3 PL 3139914 T3 PL3139914 T3 PL 3139914T3 PL 15720340 T PL15720340 T PL 15720340T PL 3139914 T3 PL3139914 T3 PL 3139914T3
- Authority
- PL
- Poland
- Prior art keywords
- disorders
- compounds
- ophthalmic diseases
- treating ophthalmic
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14167490 | 2014-05-08 | ||
| EP14170616 | 2014-05-30 | ||
| PCT/EP2015/060166 WO2015169944A1 (en) | 2014-05-08 | 2015-05-08 | Compounds for treating ophthalmic diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3139914T3 true PL3139914T3 (pl) | 2023-11-27 |
Family
ID=53051826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15720340.7T PL3139914T3 (pl) | 2014-05-08 | 2015-05-08 | Związki stosowane w leczeniu chorób i schorzeń okulistycznych |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11730716B2 (enExample) |
| EP (1) | EP3139914B1 (enExample) |
| JP (1) | JP6629840B2 (enExample) |
| KR (1) | KR102312186B1 (enExample) |
| CN (2) | CN116077665A (enExample) |
| AU (1) | AU2015257651B2 (enExample) |
| BR (1) | BR112016025997A8 (enExample) |
| CA (1) | CA2947067C (enExample) |
| CL (1) | CL2016002812A1 (enExample) |
| ES (1) | ES2960598T3 (enExample) |
| HK (1) | HK1231417A1 (enExample) |
| IL (1) | IL248732B (enExample) |
| MX (1) | MX378707B (enExample) |
| NZ (1) | NZ725574A (enExample) |
| PL (1) | PL3139914T3 (enExample) |
| SG (1) | SG11201608835VA (enExample) |
| WO (1) | WO2015169944A1 (enExample) |
| ZA (1) | ZA201607260B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| JP6629840B2 (ja) * | 2014-05-08 | 2020-01-15 | パノプテス・ファーマ・ゲーエムベーハー | 眼の疾患および障害を処置するための化合物 |
| KR20170091157A (ko) | 2014-12-23 | 2017-08-08 | 4디 파마 리서치 리미티드 | 피린 폴리펩티드 및 면역 조정 |
| PL3065748T3 (pl) | 2014-12-23 | 2018-07-31 | 4D Pharma Research Limited | Szczep Bacteroides thetaiotaomicron i jego zastosowanie w zmniejszaniu zapalenia |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| SI3240554T1 (sl) | 2015-06-15 | 2019-12-31 | 4D Pharma Research Limited, | Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni |
| EA201890050A1 (ru) | 2015-06-15 | 2018-06-29 | 4Д Фарма Рисёрч Лимитед | Композиции, содержащие бактериальные штаммы |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MD3650033T2 (ro) | 2015-06-15 | 2022-08-31 | 4D Pharma Res Ltd | Compoziții conţinând tulpini bacteriene |
| AU2016357554B2 (en) | 2015-11-20 | 2019-04-04 | Cj Bioscience, Inc. | Compositions comprising bacterial strains |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) * | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| JP6961879B2 (ja) * | 2015-12-30 | 2021-11-05 | レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ | 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置 |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| EP3520801A1 (en) | 2016-03-04 | 2019-08-07 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
| TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| IL270066B2 (en) | 2017-04-24 | 2023-10-01 | Aurigene Oncology Ltd | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| JP7212945B2 (ja) | 2017-05-22 | 2023-01-26 | フォーディー ファーマ リサーチ リミテッド | 細菌株を含む組成物 |
| TW201907931A (zh) | 2017-05-24 | 2019-03-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
| MD3804737T2 (ro) | 2017-06-14 | 2022-10-31 | 4D Pharma Res Limited | Compoziții care conțin tulpini bacteriene |
| WO2018229188A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| CN115813955A (zh) | 2017-06-14 | 2023-03-21 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| JPWO2018230713A1 (ja) * | 2017-06-16 | 2020-04-16 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
| CN110944668A (zh) | 2017-06-16 | 2020-03-31 | 学校法人同志社 | 用于治疗或预防眼部症状、障碍或疾病的包含mTOR抑制剂的药物及其应用 |
| KR102861339B1 (ko) | 2018-02-20 | 2025-09-19 | 르 라보레또레 쎄르비에르 | 삼치환 벤조트리아졸 유도체의 사용 방법 |
| WO2019170848A1 (en) | 2018-03-09 | 2019-09-12 | Panoptes Pharma Ges.M.B.H. | Ophthalmic formulation |
| WO2019175396A1 (en) * | 2018-03-16 | 2019-09-19 | Immunic Ag | Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| JP2021519334A (ja) | 2018-03-26 | 2021-08-10 | クリア クリーク バイオ， インコーポレイテッド | ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法 |
| US20210300873A1 (en) | 2020-03-20 | 2021-09-30 | Clear Creek Bio, Inc. | Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof |
| WO2021216548A1 (en) * | 2020-04-21 | 2021-10-28 | University Of Massachusetts | Methods and compositions for treatment of age-related macular degeneration |
| CN111638341A (zh) * | 2020-07-01 | 2020-09-08 | 山东凯歌智能机器有限公司 | 一种检测小细胞肺癌患者外周血循环肿瘤细胞pd-l1基因突变的试剂盒及检测方法 |
| EP4228640A1 (en) * | 2020-10-15 | 2023-08-23 | ASLAN Pharmaceuticals Pte Ltd | Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor |
| BR112023020806A2 (pt) | 2021-04-09 | 2023-12-12 | Immunic Ag | Inibidores de dhodh deuterados |
| UY40087A (es) * | 2021-12-23 | 2023-06-30 | Immunic Ag | Inhibidores de DHODH que contienen un bioisóstero de ácido carboxílico. |
| AU2023228646A1 (en) * | 2022-03-01 | 2024-09-19 | Kiora Pharmaceuticals Gmbh | Salts of a dihydroorotate dehydrogenase (dhod) inhibitor |
| CN119300819A (zh) * | 2022-03-09 | 2025-01-10 | 克奥拉制药股份有限公司 | 二氢乳清酸脱氢酶（dhod）抑制剂的多晶型物 |
| WO2024138064A1 (en) * | 2022-12-22 | 2024-06-27 | Cavalry Biosciences, Inc. | Compositions and methods for treating meibomain gland dysfunction |
| TW202506107A (zh) | 2023-06-28 | 2025-02-16 | 德商埃慕尼克股份公司 | 雜芳族dhodh抑制劑 |
| WO2026074007A1 (en) | 2024-10-02 | 2026-04-09 | Immunic Ag | Nurr1 agonists with replacement of the carboxylic acid or carboxamide moiety for use in the treatment of neurodegenerative diseases |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61103836A (ja) | 1984-10-24 | 1986-05-22 | Green Cross Corp:The | フイブロネクチン製剤 |
| DD297328A5 (de) * | 1989-08-18 | 1992-01-09 | �������@���������k���Kk�� | 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen |
| EP0834320B1 (en) | 1996-04-19 | 2004-09-01 | R-Tech Ueno, Ltd. | Albumin as active ingredient for treating corneal and conjunctival lesion and dry eye |
| HUP9701554D0 (en) | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
| WO2003006424A1 (en) | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| AU2003301347A1 (en) * | 2002-10-17 | 2004-05-04 | Control Delivery Systems, Inc. | Methods for monitoring treatment of disease |
| US7365094B2 (en) | 2002-12-23 | 2008-04-29 | 4Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| US7071355B2 (en) * | 2002-12-23 | 2006-07-04 | 4 Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| WO2004056747A1 (en) * | 2002-12-23 | 2004-07-08 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
| DE60330391D1 (de) * | 2002-12-23 | 2010-01-14 | 4Sc Ag | Cycloalken-dicarbonsäure-verbindungen als entzündungshemmende, immunmodulatorische und antiproliferative mittel |
| US7714132B2 (en) | 2004-03-11 | 2010-05-11 | Actelion Pharmaceuticals, Ltd. | Tetrahydropyridoindole derivatives |
| JP2006089485A (ja) * | 2004-08-24 | 2006-04-06 | Santen Pharmaceut Co Ltd | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| WO2007038687A2 (en) * | 2005-09-27 | 2007-04-05 | Aciont, Inc. | Ocular administration of immunosuppressive agents |
| ES2319596B1 (es) * | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| JP2009270356A (ja) | 2008-05-08 | 2009-11-19 | Yoshinobu Hayashi | アスベスト含有被覆層剥ぎ取り物の処理方法 |
| TWI530286B (zh) | 2009-05-04 | 2016-04-21 | 帕納特斯製藥格斯有限公司 | 作為抑制病毒化合物之抗發炎劑 |
| US20110021465A1 (en) * | 2009-07-23 | 2011-01-27 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome |
| US8686048B2 (en) | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
| RS60051B1 (sr) * | 2011-06-10 | 2020-04-30 | Ramscor Inc | Formulacije sa produženim oslobađanjem za isporuku proteina u oko i postupci njihove pripreme |
| KR102265277B1 (ko) * | 2014-04-11 | 2021-06-16 | 판옵테스 파르마 게스.엠.베.하. | 바이러스 억제 화합물로서의 항-염증제 |
| JP6629840B2 (ja) * | 2014-05-08 | 2020-01-15 | パノプテス・ファーマ・ゲーエムベーハー | 眼の疾患および障害を処置するための化合物 |
| JP6961879B2 (ja) | 2015-12-30 | 2021-11-05 | レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ | 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置 |
| WO2019170848A1 (en) | 2018-03-09 | 2019-09-12 | Panoptes Pharma Ges.M.B.H. | Ophthalmic formulation |
| BR112023020806A2 (pt) | 2021-04-09 | 2023-12-12 | Immunic Ag | Inibidores de dhodh deuterados |
| AU2023228646A1 (en) | 2022-03-01 | 2024-09-19 | Kiora Pharmaceuticals Gmbh | Salts of a dihydroorotate dehydrogenase (dhod) inhibitor |
| CN119300819A (zh) | 2022-03-09 | 2025-01-10 | 克奥拉制药股份有限公司 | 二氢乳清酸脱氢酶（dhod）抑制剂的多晶型物 |
-
2015
- 2015-05-08 JP JP2017510766A patent/JP6629840B2/ja not_active Expired - Fee Related
- 2015-05-08 WO PCT/EP2015/060166 patent/WO2015169944A1/en not_active Ceased
- 2015-05-08 BR BR112016025997A patent/BR112016025997A8/pt not_active Application Discontinuation
- 2015-05-08 KR KR1020167033322A patent/KR102312186B1/ko active Active
- 2015-05-08 MX MX2016014634A patent/MX378707B/es unknown
- 2015-05-08 CA CA2947067A patent/CA2947067C/en active Active
- 2015-05-08 NZ NZ725574A patent/NZ725574A/en unknown
- 2015-05-08 EP EP15720340.7A patent/EP3139914B1/en active Active
- 2015-05-08 CN CN202310101659.5A patent/CN116077665A/zh active Pending
- 2015-05-08 CN CN201580036856.7A patent/CN106572968A/zh active Pending
- 2015-05-08 SG SG11201608835VA patent/SG11201608835VA/en unknown
- 2015-05-08 PL PL15720340.7T patent/PL3139914T3/pl unknown
- 2015-05-08 HK HK17105296.1A patent/HK1231417A1/zh unknown
- 2015-05-08 AU AU2015257651A patent/AU2015257651B2/en active Active
- 2015-05-08 ES ES15720340T patent/ES2960598T3/es active Active
- 2015-05-08 US US15/309,176 patent/US11730716B2/en active Active
-
2016
- 2016-10-20 ZA ZA2016/07260A patent/ZA201607260B/en unknown
- 2016-11-03 IL IL248732A patent/IL248732B/en active IP Right Grant
- 2016-11-07 CL CL2016002812A patent/CL2016002812A1/es unknown
-
2023
- 2023-03-23 US US18/189,010 patent/US12364680B2/en active Active
-
2025
- 2025-06-24 US US19/248,216 patent/US20250381167A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016025997A8 (pt) | 2021-07-06 |
| JP2017514917A (ja) | 2017-06-08 |
| AU2015257651B2 (en) | 2020-01-23 |
| CN116077665A (zh) | 2023-05-09 |
| JP6629840B2 (ja) | 2020-01-15 |
| IL248732A0 (en) | 2017-01-31 |
| US20230285355A1 (en) | 2023-09-14 |
| BR112016025997A2 (pt) | 2017-08-15 |
| KR102312186B1 (ko) | 2021-10-14 |
| CL2016002812A1 (es) | 2017-03-17 |
| US20250381167A1 (en) | 2025-12-18 |
| CA2947067A1 (en) | 2015-11-12 |
| SG11201608835VA (en) | 2016-11-29 |
| ZA201607260B (en) | 2018-05-30 |
| AU2015257651A1 (en) | 2016-11-10 |
| KR20160147023A (ko) | 2016-12-21 |
| CA2947067C (en) | 2023-02-14 |
| US11730716B2 (en) | 2023-08-22 |
| CN106572968A (zh) | 2017-04-19 |
| MX2016014634A (es) | 2017-04-10 |
| NZ725574A (en) | 2022-08-26 |
| ES2960598T3 (es) | 2024-03-05 |
| US12364680B2 (en) | 2025-07-22 |
| IL248732B (en) | 2019-07-31 |
| HK1231417A1 (zh) | 2017-12-22 |
| EP3139914B1 (en) | 2023-07-26 |
| WO2015169944A1 (en) | 2015-11-12 |
| US20170071904A1 (en) | 2017-03-16 |
| EP3139914C0 (en) | 2023-07-26 |
| EP3139914A1 (en) | 2017-03-15 |
| MX378707B (es) | 2025-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL248732A0 (en) | Compounds for the treatment of ophthalmological diseases and disorders | |
| IL265497B (en) | Methods for treating eye diseases | |
| IL249602A0 (en) | Methods and devices for the treatment of posterior ocular disorders | |
| IL253244B1 (en) | Methods for treating retinal diseases | |
| IL246791A0 (en) | Compositions and methods for treating eye diseases | |
| SI3122878T1 (sl) | MRNA terapija za zdravljenje očesnih bolezni | |
| PT3212233T (pt) | Terapia combinada para o tratamento de doenças | |
| EP3169260A4 (en) | Methods and systems for treating diabetes and related diseases and disorders | |
| SG11201703193XA (en) | Treatment for depression and depressive disorders | |
| GB201405232D0 (en) | Apparatus and methods for the treatment of ocular disorders | |
| ZA201700416B (en) | Methods for treating or preventing ophthalmological conditions | |
| ZA201702214B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| SG11201608729RA (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders | |
| HUE049518T2 (hu) | Készítmények és eljárások a szem megbetegedéseinek kezelésére és diagnosztizálására | |
| PT3119911T (pt) | Compostos para uso no tratamento da doença de alzheimer em pacientes apoe4+/+ | |
| SMT202100082T1 (it) | Composti eteroarilici per il trattamento di malattie oftalmiche | |
| PL3164394T3 (pl) | Inhibitory GLS1 do leczenia chorób | |
| SG11201704829QA (en) | Methods and compositions for treating brain diseases | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| HUE070257T2 (hu) | Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére | |
| IL252707B (en) | Compositions and methods for treating diseases | |
| SG11201703330YA (en) | Iminosugars useful for the treatment of viral diseases | |
| EP3200795A4 (en) | Use of agents for treating fat-related disorders | |
| HK1235307A1 (en) | Methods for treating ocular diseases | |
| GB201413532D0 (en) | Combination therapy for treating hearing disorders |